TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10

Moomoo News13:32 ET · Ratings

Promising Commercial Launch and Strategic Positioning Drive Buy Rating for Humacyte

TipRanks13:25 ET · Ratings

Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital

Dow JonesFeb 26 08:37 ET · Ratings

Humacyte Is Maintained at Buy by D. Boral Capital

Dow JonesFeb 26 08:37 ET · Ratings

Humacyte Announces Commercial Launch of Symvess (Acellular Tissue Engineered Vessel-tyod) for Extremity Vascular Trauma

GlobeNewswireFeb 26 08:00 ET

When Will Humacyte, Inc. (NASDAQ:HUMA) Become Profitable?

Simply Wall StFeb 7 06:44 ET